ERBB2 and non-small cell squamous lung carcinoma: For non-small-cell lung squamous cell carcinoma (designated Lung_Nsclc_SCC) and gastric (designated Stomach) cancer cell lines, ErbB2 expression was significantly associated with sensitivity to 44% of drugs targeting ErbBs (Figure 2B).